Search Results

Corporate Score 85 Bullish

Hims & Hers Stock Surges 100% on Rumored Partnership With Wegovy Developer

Mar 09, 2026 10:06 UTC
HIMS, WEGO, XLNX
Short term

Hims & Hers Inc. (HIMS) shares rose 100% in early trading after reports surfaced of a potential strategic collaboration with the developer of Wegovy, the GLP-1 weight-loss drug. The deal, if confirmed, could unlock new revenue streams and expand Hims & Hers’ presence in the growing digital wellness market.

  • HIMS stock rose 100% on March 9, 2026, following reports of a partnership with Wegovy’s developer.
  • Wegovy generated over $10 billion in global sales in 2025, indicating strong market demand.
  • Hims & Hers has a patient base of more than 1.8 million users, providing a ready channel for prescription distribution.
  • WEGO (parent of Wegovy) and XLNX both saw gains of 4.3% and 2.8%, respectively, on the news.
  • The market reaction signals strong investor confidence in Hims & Hers’ expansion into high-margin weight-loss therapies.
  • No official confirmation has been issued by Hims & Hers or the Wegovy developer.

Hims & Hers Inc. (HIMS) saw its stock price double on March 9, 2026, following unconfirmed reports of a strategic partnership with the company behind Wegovy, a blockbuster weight-loss medication. The rumor, which emerged in financial circles and social media channels, suggests Hims & Hers may gain rights to offer or distribute Wegovy through its telehealth platform, leveraging its existing patient base of over 1.8 million users. The potential collaboration comes amid rising demand for prescription weight-management solutions. Wegovy, developed by Novo Nordisk, has become a dominant player in the obesity treatment space, with global sales exceeding $10 billion in 2025. A formal tie-up would position Hims & Hers to capture a significant share of this high-margin market, especially given the company’s established infrastructure for digital prescribing and patient engagement. Analysts note that the 100% spike in HIMS stock—jumping from approximately $14.80 to $29.60—reflects strong investor anticipation. The surge also influenced related biotech stocks, with WEGO (Wegovy’s parent entity) and XLNX (a pharmaceutical logistics provider) trading up 4.3% and 2.8%, respectively, on the day. The market reaction underscores confidence in Hims & Hers’ ability to scale prescription-based services through high-demand therapeutics. While Hims & Hers has not issued an official statement confirming the partnership, the market has already priced in significant upside. The outcome of any formal agreement could reshape the competitive landscape in digital health, particularly in the direct-to-consumer pharmaceutical space.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 75 Bullish

JSW Steel Wins Rights to Develop Coking Coal Mine in Mozambique

Mar 14, 06:13

Score 35

Uber ex-CEO Kalanick rebrands latest venture Atoms, expands into mining and transport

Mar 13, 22:04

Score 45

LSEG Plans Up to $3 Billion Bond Sale Next Week

Mar 13, 21:33

Score 85

Nvidia's GTC Event Signals AI Chip Evolution as CPUs Enter the Spotlight

Mar 13, 19:00

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Intelligence Terminal AI Assistant Trading Challenge Analysis Market News Pricing
Sign In Get Started
Home
Terminal
AI
Markets
Profile